Old drug, new target: can a common pill protect diabetic hearts?
NCT ID NCT05949281
Summary
This study is testing if adding a low dose of colchicine, an existing anti-inflammatory drug, to standard diabetes care can reduce inflammation and lower the risk of heart disease in adults with type 1 diabetes. About 100 participants, who have type 1 diabetes and signs of inflammation or high heart disease risk, will take either colchicine or a placebo pill daily for 6 to 12 months. Researchers will track markers of inflammation, heart health, and blood sugar control during treatment and for five years afterward.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Center for Clinical Metabolic Research, Gentofte Hospital
Hellerup, Capital Region, 2900, Denmark
Conditions
Explore the condition pages connected to this study.